Press release content from Business Wire. The AP news staff was not involved in its creation.
Athersys Announces CEO Transition
CLEVELAND, Ohio (BUSINESS WIRE) Feb 16, 2021
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem ® cell therapy, today announced that Dr. Gil Van Bokkelen has stepped down as Chairman and Chief Executive Officer, effective immediately. The Athersys Board has appointed William (B.J.) Lehmann, the Company’s President and Chief Operating Officer, as Interim Chief Executive Officer. Dr. Ismail Kola, Lead Director of the Athersys Board, has been appointed Chairman of the Board.
The Company’s Board is commencing a comprehensive search process to identify a permanent CEO. The Board intends to identify and select a CEO who can guide Athersys in the commercial stage.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Athersys Announces Cooperation Agreement With HEALIOS K.K.
February 16, 2021 GMT
CLEVELAND (BUSINESS WIRE) Feb 16, 2021
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem ® cell therapy, today announced that it has entered into a cooperation agreement with HEALIOS K.K. (“Healios”), the Company’s largest shareholder and one of its commercial partners, and Dr. Hardy TS Kagimoto, a member of the Company’s Board and the Chairman and Chief Executive Officer of Healios. The cooperation agreement is intended to reaffirm the mutual commitment to collaborative development of MultiStem in Japan.
News Category Global Banking & Finance Reviews
UTHealth in Houston and Athersys Announce Commencement of Patient Enrollment in a Phase 2 Trial Evaluating MultiStem® Cell Therapy in Trauma
UTHealth in Houston and Athersys Announce Commencement of Patient Enrollment in a Phase 2 Trial Evaluating MultiStem® Cell Therapy in Trauma The University of Texas Health Science Center at Houston (UTHealth) and Athersys, Inc. (NASDAQ: ATHX) announced today that the first patient has been enrolled in a clinical study evaluating MultiStem cell therapy for the potential early treatment of traumatic injuries and the subsequent complications that result. The MATRICS-1 (MultiStem Administration for Trauma Related Inflammation and Complications) study is being conducted at Memorial Hermann-Texas Medical Center, one of the busiest Level 1 trauma centers in the United States.